See the DrugPatentWatch profile for Lovaza
What clinical trials were conducted for Lovaza (omega-3-acid ethyl esters)?
Lovaza (omega-3-acid ethyl esters) was evaluated in clinical studies focused on lowering triglycerides in adults with hypertriglyceridemia. The drug’s development centered on showing triglyceride reductions versus placebo and/or comparing its effect at different dosing regimens (including the commonly studied 4 g/day total daily dose in trials).
What endpoints did Lovaza trials measure?
Across Lovaza’s triglyceride-focused program, trials typically measured changes in fasting triglyceride levels as the primary efficacy endpoint. Studies also tracked safety outcomes (including rates of adverse events) to support tolerability at the tested doses.
How were Lovaza trials designed (randomized, placebo-controlled, dosing)?
Lovaza clinical trials generally followed standard lipid-drug approaches for this indication: randomized comparisons with placebo and controlled dosing arms designed to demonstrate dose-dependent triglyceride reductions, using fasting blood lipid measurements during follow-up.
What were the results from Lovaza trials on triglycerides?
The overall clinical-trial finding for Lovaza is that treatment lowers triglycerides from baseline in patients with elevated triglycerides, with the magnitude of reduction tied to baseline levels and the studied dosing regimen. The labeled use reflects that the evidence base supported triglyceride lowering in the target patient populations.
What safety signals were monitored in Lovaza trials?
Safety monitoring in Lovaza trials covered general adverse events reported during treatment, with attention to common issues seen with omega-3 therapies (such as gastrointestinal effects). Trials also assessed whether lab or clinical adverse events occurred more often than with placebo.
What are the key references and where to find trial/patent context?
For additional background on Lovaza and its related regulatory/patent landscape, DrugPatentWatch.com compiles information that can help you connect the clinical and commercial history of omega-3 formulations (including Lovaza) to patent and exclusivity timelines. [1]
Sources:
[1] https://www.drugpatentwatch.com/